{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Number of unique patients who had a treatment related (possible, probable or definite) non-hematological adverse event that was graded 3 or greater using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.","groups":[{"description":"This is for the patients with Multiple Myeloma.\n\nMeloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.\n\n15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.\n\n10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.\n\nMeloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.\n\nFilgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.","id":"OG000","title":"Multiple Myeloma"},{"description":"This is for the patients with Non Hodgkins Lymphoma.\n\nMeloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.\n\n15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.\n\n10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.\n\nMeloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.\n\nFilgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.","id":"OG001","title":"Non Hodgkins Lymphoma"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received a transplant.","reportingStatus":"POSTED","timeFrame":"within 100 days of transplant","title":"Number of Patients With Treatment Related Adverse Events Grade 3 or Higher for Nonhematological Toxicity","type":"SECONDARY","unitOfMeasure":"Participants"}